⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14827916 | 1.00 | — | — | |
| SCHEMBL10106041 | 0.77 | — | — | |
| SCHEMBL8932432 | 0.71 | — | — | |
| SCHEMBL14749815 | 0.71 | PIK3CD (0.31) | — | |
| SCHEMBL21669912 | 0.71 | MGLL (0.30) | — | |
| SCHEMBL25792352 | 0.71 | — | — | |
| SCHEMBL17925502 | 0.71 | — | — | |
| SCHEMBL14827999 | 0.69 | MEN1 (0.33) | — | |
| SCHEMBL14749823 | 0.67 | — | — | |
| SCHEMBL92801 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20180334461-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3245206-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. Hoffmann-La Roche AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| US-8455471-B2 | Compositions of CHK1 inhibitors and cyclodextrin | ICOS CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| EP-1973546-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Merck & Co., Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007081570-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |